Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.

Published

Journal Article

The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.

Full Text

Duke Authors

Cited Authors

  • Chaudhry, V; Cornblath, DR; Griffin, JW; O'Brien, R; Drachman, DB

Published Date

  • January 9, 2001

Published In

Volume / Issue

  • 56 / 1

Start / End Page

  • 94 - 96

PubMed ID

  • 11148242

Pubmed Central ID

  • 11148242

International Standard Serial Number (ISSN)

  • 0028-3878

Digital Object Identifier (DOI)

  • 10.1212/wnl.56.1.94

Language

  • eng

Conference Location

  • United States